price
Get this report for lesser with our subscription services
While subscription services provide a hassle-free experience and cost savings.
GO TO SECTION:
Speak With Us
Want to know more about the report or any specific requirement?
About The Report
DOWNLOAD SAMPLE“Navigate the complexities of the Europe Cell & Gene Therapy Market with our comprehensive report. This analysis allows you to identify emerging contenders with robust product portfolios and craft effective counter strategies to secure your competitive edge.”
- The Europe cell and gene therapy market, valued at $2.17 billion in 2022, is expected to witness robust growth with a CAGR of 38.20% between 2022 and 2028. This substantial growth is driven primarily by a rising target patient population, support from regulatory bodies, and moderate reimbursement coverage. Germany, currently the largest market in Europe, is expected to maintain a significant share of the market throughout the forecast period, closely followed by France and the UK.
The market expansion is fueled by several factors, including increased access to healthcare, courtesy of the region's well-established healthcare infrastructure, and a high level of healthcare spending. These factors, combined with a growing focus on R&D to develop novel cell and gene therapies, are anticipated to contribute significantly to the market's growth.
The market has also seen an upsurge in the utilization of Contract Manufacturing Organizations (CMOs), which have developed innovative vectors to expedite product manufacturing using a highly integrated approach. These organizations provide an advanced platform in the market to manufacture the products required for vendors.
The market has seen a proliferation of clinical trials, with vendors actively seeking regulatory approval in various countries and regions with high untapped potential. Vendors primarily target Europe due to its established facilities for cell and gene therapy product development. The increasing list of potential investigational cell and gene therapy products encourages many companies to employ acquisitions as a strategic approach to further penetrate the market.
The competitive landscape in the cell and gene therapy market in Europe is becoming increasingly intense, with several global players offering a diverse range of products. The market is currently dominated by major players such as Novartis, Gilead Sciences, Spark Therapeutics (Roche), Amgen, and Orchard Therapeutics. These players are actively focusing on strategic acquisitions, licensing, and collaboration agreements with emerging players to enter the cell and gene therapy market and gain access to commercially launched products.
Client Oriented Solutions
Arizton provides in-depth market insights and intelligence across various sectors, including Automotive & Mobility, Data Centers, Consumer Goods, and Healthcare & Lifesciences.
Analytical Approach
Arizton focuses on providing information related to key issues facing the industry, Existing market landscape, regulatory concerns, risk & opportunities, technology evolution, future commercial potential.
Comprehensive Data Repository
The reports provide historical and forecast data for 20+ key countries worldwide. We track product approvals/launches, M&A activities, and collaboration/partnership activities.
Publication Analysis
Arizton delivers timely industry updates and customized insights by analyzing peer-reviewed research and business publications.
price
Get this report for lesser with
our subscription services
Summary
- The Europe cell and gene therapy market was valued at $2.17 billion in 2022 and is projected to reach at $15.15 billion in 2028, with a compound annual growth rate (CAGR) of 38.20%, during the study period.
- Among all commercial cell & gene therapies, Zolgensma is the first and only product to achieve the blockbuster drug tag. Zolgensma generated a revenue of $1.37 billion in 2022 and could reach around $5.00 billion by 2026.
- Drug developers are prioritizing developing and commercializing CAR-T cell-based gene therapies. Globally, more than 1,000 clinical trials are being conducted on CAR T-cell therapies, of which at least 500 clinical trials are for cancer alone. Kymriah (Novartis), Yescarta (Gilead Sciences), Tecartus (Gilead Sciences), Breyanzi (Bristol Myers Squibb), Abecma (Bristol Myers Squibb), and Carvykti (Janssen Biotech / Legend Biotech) are the commercial CAR-T therapies available in the market.
- In 2022, Germany was the first-largest market in Europe, followed by France and the UK. The market is majorly driven by an increased target patient population, regulatory body support, and higher access to healthcare due to well-established healthcare infrastructure.
- The European Medicines Agency (EMA) has approved more than nineteen cell and gene therapy drugs, but the new product pipeline has approximately 193 investigational therapies, with more than half of these in Phase 2 clinical trials. Oncology and rare diseases remain the top areas targeted by gene therapies from preclinical through pre-registration.
- Approximately 1,564 clinical trials are under investigation for various cell and gene therapies in Europe. This increase could be because of increased funding for cell and gene therapy. The industry-sponsored trials are continued to dominate with a share of 78.71%.
- Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of the presence of a large pool of target patient populations with chronic diseases such as cancer, genetic and rare diseases, and other complex disorders.
PRODUCT SEGMENTATION & FORECAST
- Product Type
▪ Cell therapy
▪ Gene therapy
- Application type
- Oncology
- Genetic Disorders
- Dermatology
- Musculoskeletal
- Others
- End-user type
- Hospitals
- Cancer Care Centers
- Others
Europe Cell & Gene Therapy Market Vendor List
Gene Therapy Vendors
- Novartis
- Gilead Sciences
- Amgen
- Roche
- Orchard Therapeutics
- BioMarin Pharmaceutical (BioMarin)
- PTC Therapeutics
- Bristol-Myers Squibb (BMS)
- Legend Biotech
- bluebird bio
- Human Stem Cells Institute PJSC (HSCI)
Cell Therapy Vendors
- Organogenesis
- Smith & Nephew
- CHIESI Farmaceutici
- CollPlant
- CO.DON
- Takeda Pharmaceutical Company
- Nipro
- Vericel
- NuVasive
Key Emerging Investigational Vendors
- Adaptimmune Therapeutics
- AgenTus Therapeutics
- Autolus Therapeutics
- Cellectis
- Celyad
- CombiGene AB
- Eukarys
- FREELINE Therapeutics
- Innoskel
- Psioxus Therapeutics
- Sparing Vision
- UniQure
Report Preview
DOWNLOAD SAMPLEPlease Note : Arizton critically analyzes the industry and market sectors to provide reliable and valuable market intelligence. The research-based knowledge empowers clients to formulate intelligent strategies, resulting in creative, cost-effective, and efficient execution.
Table Of Contents
- Executive Summary
- Introduction
- Key Findings
- Key Developments
- Europe: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- Application type
- End-user type
- EU5: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- Application type
- End-user type
- ROEU: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- Application type
- End-user type
- Germany: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- France: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- UK: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- Italy: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- Italy: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
- Product type
- Cell & Gene Therapy Market Drivers
- Cell & Gene Therapy Market Trends
- Cell & Gene Therapy Market Constraints
- Cell & Gene Therapy - Marketed Drugs Overview
- Cell & Gene Therapy - Pipeline Drugs Overview
- Cell & Gene Therapy - Competitive Landscape
- Cell & Gene Therapy - Key Players
- Cell & Gene Therapy - Key Company Profiles
- Cell & Gene Therapy - Mergers & Acquisitions
- Cell & Gene Therapy - Key Strategic Recommendations
- Pricing, Reimbursement and Market Access
- Contract Manufacturing Organizations (CMOs)
- Regulatory Landscape and Policies
- Research Methodology
- Abbreviations
- About Arizton
- Exhibit 1: Projected Revenue of Cell & Gene Therapy Market in Europe (2022 – 2028)
- Exhibit 2: Projected Revenue of Cell & Gene Therapy Market in Europe by Product type
(2022 – 2028)
- Exhibit 3: Projected Revenue of Cell & Gene Therapy Market in Europe by Application type
(2022 – 2028)
- Exhibit 4: Projected Revenue of Cell & Gene Therapy Market in Europe by End-user type
(2022 – 2028)
- Exhibit 5: Projected Revenue of Cell & Gene Therapy Market in EU5 (2022 – 2028)
- Exhibit 6: Projected Revenue of Cell & Gene Therapy Market in EU5 by Product type
(2022 – 2028)
- Exhibit 7: Projected Revenue of Cell & Gene Therapy Market in EU5 by Application type
(2022 – 2028)
- Exhibit 8: Projected Revenue of Cell & Gene Therapy Market in EU5 by End-user type
(2022 – 2028)
- Exhibit 9: Projected Revenue of Cell & Gene Therapy Market in ROEU (2022 – 2028)
- Exhibit 10: Projected Revenue of Cell & Gene Therapy Market in ROEU by Product type
(2022 – 2028)
- Exhibit 11: Projected Revenue of Cell & Gene Therapy Market in ROEU by Application type
(2022 – 2028)
- Exhibit 12: Projected Revenue of Cell & Gene Therapy Market in ROEU by End-user type (2022 –2028)
- Exhibit 13: Projected Revenue of Cell & Gene Therapy Market in Germany (2022 – 2028)
- Exhibit 14: Projected Revenue of Cell & Gene Therapy Market in Germany by Product type
(2022 – 2028)
- Exhibit 15: Projected Revenue of Cell & Gene Therapy Market in France (2022 – 2028)
- Exhibit 16: Projected Revenue of Cell & Gene Therapy Market in France by Product type (2022 – 2028)
- Exhibit 17: Projected Revenue of Cell & Gene Therapy Market in UK (2022 – 2028)
- Exhibit 18: Projected Revenue of Cell & Gene Therapy Market in UK by Product type
(2022 – 2028)
- Exhibit 19: Projected Revenue of Cell & Gene Therapy Market in Italy (2022 – 2028)
- Exhibit 20: Projected Revenue of Cell & Gene Therapy Market in Italy by Product type
(2022 – 2028)
- Exhibit 21: Projected Revenue of Cell & Gene Therapy Market in Spain (2022 – 2028)
- Exhibit 22: Projected Revenue of Cell & Gene Therapy Market in Spain by Product type
(2022 – 2028)
- Exhibit 23: Marketed Drugs Overview in Cell & Gene Therapy Market
- Exhibit 24: Pipeline Drugs Overview in Cell & Gene Therapy Market
Table 1: Key Market Trends in Cell & Gene Therapy Market
Table 2: Key Market Enablers in Cell & Gene Therapy Market
Table 3: Key Market Constraints in Cell & Gene Therapy Market
Table 4: Recent Approvals in Cell & Gene Therapy Market
Table 5: Near-term Approvals in Cell & Gene Therapy Market
Table 6: Strategic Recommendations in Cell & Gene Therapy Market
Interested in this report?
Other Related Reports
Frequently Asked Questions
Download Free Sample
Download free market research reports by Focus Reports covering, industry overview, market size, market share.
Speak with our analyst
Download free market research reports by Arizton covering, industry overview, market size, market share, markets trends.
Our Clients
